Pilot Study to Evaluate the Plasma Profile of Revifast

NCT ID: NCT04258306

Last Updated: 2020-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2019-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate in 6 subjects aged between 18 and 60 years the peak blood (plasma profile) of two formulations, indistinguishable from each other, containing:

A) 180 mg natural Resveratrol (Polygonum cuspidatum 98%) B) 180 mg of Revifast® (resveratrol from supported on Magnesium hydroxide).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be randomized, controlled, single blind, cross-over, using the two granular compounds in capsules A and B, indistinguishable from each other, dissolved in aqueous solution and administered orally. either A:180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.

B) 180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold \& Zucc. Root supported on Magnesium hydroxide).

Cross-over refers to a type of clinical study in which each individual receives each of the treatments consecutively.

PHASE I: The subjects will be given, on the first day, in the morning on an empty stomach, a solution of content A or B obtained by dissolving the contents of the capsule in water which will then be taken orally. Samples of 2 ml of venous blood in a tube containing EDTA will be taken from a vein in the arm using a cannula at 0 min (fasting before administration), 15 min, 30 min, 60 min, 90 min, 120 min, 180 min .

WASH-OUT: 1 day. PHASE II: On the third day, the person who had taken the solution A will take the solution B, and vice versa, with the same methods and times described above.

The study will have a total duration of 6 weeks divided as follows:

* Pre-monitoring phase, enrollment of subjects, random assignment in two arms 1 and 2 each consisting of 3 subjects and signature of the informative consent regarding the adhesion to the study protocol (1 week);
* 1 week for taking samples and storing them for routine chemical / biochemical analyzes carried out at the Crabion S.R.L. accredited center based in Corciano in via Amilcare Ponchielli 8 (on the first day, arm 1 will start treatment with solution A; on the second day, this arm will wash-out and arm 2 will start treatment with solution A; on third day on arm 1 will start the treatment with solution B and arm 2 will wash-out; on the fourth day arm 2 will carry out the treatment with solution B; once the routine analyzes have been carried out, on the fifth day the frozen samples will be sent to the Department of chemistry, biology and biotechnology of the University of Perugia for subsequent extraroutine analyzes).
* 2 weeks for carrying out the pharmacological and metabolomic analyzes of extraroutins performed at the Department of chemistry, biology and biotechnology of the University of Perugia;
* 2 weeks for carrying out statistical tests and processing the data obtained.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nutrient; Excess Product Use Issue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The subjects will be given, on the first day, in the morning on an empty stomach, a solution of content A or B obtained by dissolving the contents of the capsule in water which will then be taken orally. Samples of 2 ml of venous blood in a tube containing EDTA will be taken from a vein in the arm using a cannula at 0 min (fasting before administration), 15 min, 30 min, 60 min, 90 min, 120 min, 180 min. WASH-OUT on the second day. On the third day, the person who had taken the solution A will take the solution B, and vice versa, with the same methods and times described above.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
Single blind, the subject, but not the responsible investigator, does not know which of the two possible treatments he receives.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Resveratrol

180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.

Group Type ACTIVE_COMPARATOR

pure resveratrol

Intervention Type DIETARY_SUPPLEMENT

resveratrol extracted from Polygonum cuspidatum resveratrol (98%).

REVIFAST

180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold \& Zucc. Root supported on Magnesium hydroxide).

Group Type EXPERIMENTAL

Revifast

Intervention Type DIETARY_SUPPLEMENT

Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Revifast

Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).

Intervention Type DIETARY_SUPPLEMENT

pure resveratrol

resveratrol extracted from Polygonum cuspidatum resveratrol (98%).

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

trans-resveratrol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects naive to taking resveratrol, willing and able to understand and sign an informed consent;
* Normal blood and chemical tests: blood count, lipid structure, kidney and liver function, inflammatory structure (Tnfα, reactive protein C, ESR), glycemic profile (Fasting blood glucose, HbA1C, insulinemia, Homa Index).

Exclusion Criteria

* Chronic pathologies (chronic renal failure, chronic hepatocellular insufficiency, autoimmune diseases, chronic inflammatory bowel diseases, diabetes mellitus, end-stage neoplasms, symptomatic chronic ischemic heart disease);
* severe arterial hypertension;
* High degree hypercholesterolaemia;
* Up to two previous days' intake of red wine not exceeding 2 glasses / day for men and 1 glass / day for women;
* Up to two previous days intake of foods containing resveratrol (red grapes, blueberries, dried fruit);
* Age \<18 years;
* Poor compliance;
* Taking dietary supplements containing antioxidants;
* Untreated hypothyroidism;
* Pregnant and breastfeeding women
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bernard Fioretti

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bernard Fioretti

Associate Professor of General Phisiology

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Deparment of Chemistry, Biology and Biotechnology

Perugia, PG, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RVF01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Guided Metabolic Detox Program
NCT06061289 COMPLETED NA